Garth Lees-Rolfe - Jan 3, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Financial Officer
Signature
/s/ Garth Lees-Rolfe
Stock symbol
IKT
Transactions as of
Jan 3, 2025
Transactions value $
$0
Form type
4
Date filed
1/7/2025, 06:43 PM
Previous filing
Apr 2, 2024
Next filing
Jan 22, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +471K $0.00 471K Jan 3, 2025 Common Stock 471K $1.26 Direct F1
transaction IKT Stock Option (Right to Buy) Award $0 +235K $0.00 235K Jan 3, 2025 Common Stock 235K $1.45 Direct F2
transaction IKT Stock Option (Right to Buy) Award $0 +433K $0.00 433K Jan 3, 2025 Common Stock 433K $1.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vested and became exercisable on October 9, 2024.
F2 The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
F3 The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.